Jeffrey Lieberman M.D


Select Journal Articles

Lieberman JA. Back to the Future—The Therapeutic Potential of Psychedelic Drugs. N Engl J Med 2021; 384: 1460-1461.

Lieberman JA, First MB. Psychotic Disorders. N Engl J Med 2018; 379:270-280. doi: 10.1056/NEJMra1801490

Ballon JS, Pajvani UB, Mayer LE, Freyberg Z, Freyberg R, Contreras I, Rosenbaum M, Leibel RL, Lieberman JA. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. J Psychopharmacol. 2018; 32(5):533-540. doi: 10.1177/0269881118754708

Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall MM, Corcoran CM, Schobel SA, Small SA. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry. 2018; 23:1764-1772. doi: 10.1038/mp.2017.249

Lieberman JA, Ehrhardt AA, Simpson HB, Arbuckle MR, Fyer AJ, Essock SM. Eliminating the Glass Ceiling in Academic Psychiatry. Acad Psychiatry. 2017; 42:523-529.  doi: 10.1007/s40596-017-0810-5

DuPont RF, Lieberman JA. Young brains on drugs. Science [Editorial] 2014; 344(6184): 557. doi: 10.1126/science.1254989

Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. JAMA 2013; 310(7):689-690.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. [Feature Review] Mol Psychiatry 2012; 12:1206-1227.

Lieberman JA, Stroup TS: The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry 2011; 168(8):770-775

Merrill DB, Girgis RR, Bickford LC, Vorel SR, Lieberman JA: Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry 2010; 167(4):381-386.

Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup TS: Science and recovery in schizophrenia. Psychiatric Services 2008; 59:487-496

Corcoran C, Lieberman JA: The impossible dream: can psychiatry prevent psychosis? Early Intervention in Psychiatry 2007; 1:219-221

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353(12):1209-1223.

Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M: Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 2005; 62(4):361-370

Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology and therapeutic approaches. Biological Psychiatry 2001; 50(11):884-897.

Lieberman JA: Starting a career in psychiatric research: The Lessons of Experience. Academic Psychiatry 2001; 25:28-30

Lieberman JA, Fenton WS: Delayed detection of psychosis: Causes, consequences, and effect on public health. American Journal of Psychiatry 2000; 157:1727-1734

Lieberman JA: Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 1999; 46(6):729-739

Robinson DG, Woerner MG, Alvir JMa.J, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 1999; 56(3):241-247

Robinson DG, Woerner MG, Alvir JMa.J, Geisler S. Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999; 156(4):544-549

Lieberman JA, Rush AJ. Redefining the role of psychiatry in medicine. American Journal of Psychiatry 1996; 153(11):1388-1397

Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine 1993; 329:162-167

Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first episode schizophrenia. American Journal of Psychiatry 1992; 149:1183-1188

Lieberman JA, Yunis J, Egea E, Kane JM, Yunis EJ: HLA-B38, DR4, DQW3 and Clozapine Induced Agranulocytosis in Jewish Patients with Schizophrenia. Archives of General Psychiatry 1990; 47:945-948

Placeholder Image